<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106651</url>
  </required_header>
  <id_info>
    <org_study_id>CR017014</org_study_id>
    <secondary_id>28431754DIA3010</secondary_id>
    <nct_id>NCT01106651</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of 2 different doses of
      canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2
      diabetes mellitus (T2DM) with inadequate control on their current diabetes treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Canagliflozin is a drug that is being tested to see if it may be useful in treating patients
      diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (study drug assigned by
      chance), double-blind (neither the patient or the study doctor will know the name of the
      assigned treatment), placebo-controlled, parallel-group, 3-arm (3 treatment groups)
      multicenter study to determine the efficacy, safety, and tolerability of canagliflozin (100
      mg and 300 mg) compared to placebo (a capsule that looks like all the other treatments but
      has no real medicine) in patients with T2DM who are not achieving an adequate response from
      current antihyperglycemic therapy to control their diabetes. Approximately 720 older (55 to
      80 years of age) patients with T2DM who are either not on an antihyperglycemic agent or who
      are receiving treatment with a stable regimen of antihyperglycemic agent(s) and have
      inadequate glycemic (blood sugar) control will receive once daily treatment with
      canagliflozin (100 mg or 300 mg) or placebo capsules for 104 weeks (includes 26 weeks of
      double-blind treatment followed by a 78-week extension period). In addition, all patients
      will take stable doses of the antihyperglycemic agent(s) that they were taking before entry
      in the study for the duration of the study. Patients will participate in the study for
      approximately 108 weeks. During the study, if a patient's fasting blood sugar remains high
      despite treatment with study drug, the patient will receive treatment with an
      antihyperglycemic agent (rescue therapy) that is considered clinically appropriate and
      consistent with local prescribing information. During treatment, patients will be monitored
      for safety by review of adverse events, results from laboratory tests, measures of bone
      health, 12-lead electrocardiograms (ECGs), vital signs measurements, body weight, physical
      examinations, and self-monitored blood glucose (SMGB) measurements. The primary outcome
      measure in the study is the effect of canagliflozin relative to placebo on hemoglobin A1c
      (HbA1c) after 26 weeks of treatment. Study drug will be taken orally (by mouth) once daily
      before the first meal each day unless otherwise specified. All patients will take
      single-blind placebo capsules for 2 weeks before randomization. After randomization, patients
      will take double blind canagliflozin (100 mg or 300 mg) or matching placebo for 104 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With HbA1c &lt;7% at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>Region percent total fat = body fat as a percentage of (body fat + lean body mass + bone mass content). The table below shows the least-squares (LS) mean change in region percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific dual-energy X-ray absorptiometry (DXA) analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tissue Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>Tissue percent total fat = body fat as a percentage of body fat + lean body mass. The table below shows the least-squares (LS) mean change in tissue percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 or each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in lumbar spine BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Distal Forearm Bone Mineral Density (BMD) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in distal forearm BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Femoral Neck Bone Mineral Density (BMD) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in femoral neck BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in total hip BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">716</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 100 mg</intervention_name>
    <description>One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 300 mg</intervention_name>
    <description>One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.</description>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihyperglycemic agent(s)</intervention_name>
    <description>Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM and may be currently treated with a stable
             regimen of antihyperglycemic agent(s)

          -  Patients in the study must have a HbA1c between &gt;=7 and &lt;=10.0%

          -  Patients must have a fasting plasma glucose (FPG) &lt;270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, or a
             severe hypoglycemic episode within 6 months before screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Citrus Heights</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pahrump</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fremantle</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg Heights</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meadowbrook</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John'S</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Venissieux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessalonikis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sha Tin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pozuelo De Alarcon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>GÃ¶teborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruderholz</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>India</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Estonia</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <results_first_submitted>April 1, 2013</results_first_submitted>
  <results_first_submitted_qc>April 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2013</results_first_posted>
  <disposition_first_submitted>March 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2012</disposition_first_posted>
  <last_update_submitted>October 27, 2014</last_update_submitted>
  <last_update_submitted_qc>October 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Canagliflozin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Hemoglobin A1c</keyword>
  <keyword>Bone</keyword>
  <keyword>Type 2 diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study evaluated the efficacy and safety of canagliflozin in older patients with type 2 diabetes mellitus with inadequate control on their current diabetes treatment regimen. The study began on 07 June 2010 and ended on 23 May 2013. Patients were recruited from 90 study centers located in 17 countries worldwide.</recruitment_details>
      <pre_assignment_details>716 patients were randomly allocated to the 3 treatment arms. 714 patients received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set and safety analysis set. Participant flow is presented for Baseline to Week 104 (Overall Study).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
        </group>
        <group group_id="P3">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="241"/>
                <participants group_id="P3" count="236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 100 mg</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
        </group>
        <group group_id="B3">
          <title>Canagliflozin 300 mg</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="237"/>
            <count group_id="B2" value="241"/>
            <count group_id="B3" value="236"/>
            <count group_id="B4" value="714"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="141"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.2" spread="6.21"/>
                    <measurement group_id="B2" value="64.3" spread="6.46"/>
                    <measurement group_id="B3" value="63.4" spread="5.99"/>
                    <measurement group_id="B4" value="63.6" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>AUSTRALIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COLOMBIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GREECE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HONG KONG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>INDIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NEW ZEALAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH AFRICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWEDEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWITZERLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKRAINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HbA1c From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.063"/>
                    <measurement group_id="O2" value="-0.60" spread="0.063"/>
                    <measurement group_id="O3" value="-0.73" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.069</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.708</ci_lower_limit>
            <ci_upper_limit>-0.436</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.070</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.841</ci_lower_limit>
            <ci_upper_limit>-0.566</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With HbA1c &lt;7% at Week 26</title>
        <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
        <time_frame>Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With HbA1c &lt;7% at Week 26</title>
          <description>The table below shows the percentage of patients with HbA1c &lt;7% at Week 26 in each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the percentage.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0"/>
                    <measurement group_id="O2" value="47.7"/>
                    <measurement group_id="O3" value="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.93</ci_lower_limit>
            <ci_upper_limit>4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.89</ci_lower_limit>
            <ci_upper_limit>6.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in FPG from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.39" spread="2.875"/>
                    <measurement group_id="O2" value="-18.1" spread="2.860"/>
                    <measurement group_id="O3" value="-20.3" spread="2.920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-25.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.147</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.68</ci_lower_limit>
            <ci_upper_limit>-19.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-27.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.179</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.97</ci_lower_limit>
            <ci_upper_limit>-21.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.3"/>
                    <measurement group_id="O2" value="-2.4" spread="0.3"/>
                    <measurement group_id="O3" value="-3.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-3.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</title>
        <description>The table below shows the least-squares (LS) mean change in total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</title>
          <description>The table below shows the least-squares (LS) mean change in total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.336"/>
                    <measurement group_id="O2" value="-1.87" spread="0.332"/>
                    <measurement group_id="O3" value="-2.38" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.379</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.339</ci_lower_limit>
            <ci_upper_limit>-0.842</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-2.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.371</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.833</ci_lower_limit>
            <ci_upper_limit>-1.368</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</title>
        <description>Region percent total fat = body fat as a percentage of (body fat + lean body mass + bone mass content). The table below shows the least-squares (LS) mean change in region percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific dual-energy X-ray absorptiometry (DXA) analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Region Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</title>
          <description>Region percent total fat = body fat as a percentage of (body fat + lean body mass + bone mass content). The table below shows the least-squares (LS) mean change in region percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific dual-energy X-ray absorptiometry (DXA) analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.270"/>
                    <measurement group_id="O2" value="-1.03" spread="0.268"/>
                    <measurement group_id="O3" value="-1.18" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Region percent total fat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.305</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.633</ci_lower_limit>
            <ci_upper_limit>-0.428</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Region percent total fat</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.300</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.772</ci_lower_limit>
            <ci_upper_limit>-0.587</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Tissue Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</title>
        <description>Tissue percent total fat = body fat as a percentage of body fat + lean body mass. The table below shows the least-squares (LS) mean change in tissue percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tissue Percent Total Fat From Baseline to Week 26 in a Subset of Patients Undergoing Specific Dual-energy X-ray Absorptiometry (DXA) Analysis for Body Composition</title>
          <description>Tissue percent total fat = body fat as a percentage of body fat + lean body mass. The table below shows the least-squares (LS) mean change in tissue percent total fat from Baseline to Week 26 for each treatment group in patients randomized to the subset of patients undergoing specific DXA analysis for body composition. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.280"/>
                    <measurement group_id="O2" value="-1.04" spread="0.278"/>
                    <measurement group_id="O3" value="-1.18" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.316</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.677</ci_lower_limit>
            <ci_upper_limit>-0.430</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.311</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.812</ci_lower_limit>
            <ci_upper_limit>-0.584</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure (SBP) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean change in SBP from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.039"/>
                    <measurement group_id="O2" value="-3.52" spread="1.035"/>
                    <measurement group_id="O3" value="-6.79" spread="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-4.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.854</ci_lower_limit>
            <ci_upper_limit>-2.401</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-7.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.147</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.14</ci_lower_limit>
            <ci_upper_limit>-5.641</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change in triglycerides from Baseline to Week 26 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="3.4"/>
                    <measurement group_id="O2" value="2.8" spread="3.3"/>
                    <measurement group_id="O3" value="8.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.194</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-4.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.846</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>8.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 or each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change in HDL-C from Baseline to Week 26 or each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in the LS mean change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="206"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.2"/>
                    <measurement group_id="O2" value="6.8" spread="1.2"/>
                    <measurement group_id="O3" value="6.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>7.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>4.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>7.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in lumbar spine BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in lumbar spine BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="0.3"/>
                    <measurement group_id="O3" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Distal Forearm Bone Mineral Density (BMD) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in distal forearm BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Distal Forearm Bone Mineral Density (BMD) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in distal forearm BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="208"/>
                <count group_id="O3" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.3"/>
                    <measurement group_id="O2" value="-0.7" spread="0.3"/>
                    <measurement group_id="O3" value="-0.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Femoral Neck Bone Mineral Density (BMD) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in femoral neck BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Femoral Neck Bone Mineral Density (BMD) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in femoral neck BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.3"/>
                    <measurement group_id="O2" value="-0.7" spread="0.3"/>
                    <measurement group_id="O3" value="-0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26</title>
        <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in total hip BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 mg</title>
            <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Hip Bone Mineral Density (BMD) From Baseline to Week 26</title>
          <description>The table below shows the least-squares (LS) mean percent change from Baseline to Week 26 in total hip BMD for each treatment group as assessed by dual-energy X-ray absorptiometry (DXA). The statistical analyses show the treatment differences (ie, each canagliflozin group minus placebo) in LS mean percent change.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Last-observation-carried-forward method used for missing Week 26 values. Measurements taken pre-rescue used as last observation in patients receiving glycemic rescue therapy. Table includes only patients with both baseline and post baseline values.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="209"/>
                <count group_id="O3" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.2"/>
                    <measurement group_id="O2" value="-0.9" spread="0.2"/>
                    <measurement group_id="O3" value="-1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the duration of the study (104 weeks).</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Events&quot; table are based upon a cut-off of greater than or equal to 5 percent of patients experiencing the adverse event in any treatment arm. MEDDRA 14.0 used for Week 26 results/ MEDDRA 16.0 used for Week 104 results.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo: Baseline to Week 26</title>
          <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 100 mg: Baseline to Week 26</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E3">
          <title>Canagliflozin 300 mg: Baseline to Week 26</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry. Data are presented for Baseline to Week 26.</description>
        </group>
        <group group_id="E4">
          <title>Placebo: Baseline to Week 104</title>
          <description>Each patient received matching placebo once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry. Data are presented for Baseline to Week 104.</description>
        </group>
        <group group_id="E5">
          <title>Canagliflozin 100 mg: Baseline to Week 104</title>
          <description>Each patient received 100 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry. Data are presented for Baseline to Week 104</description>
        </group>
        <group group_id="E6">
          <title>Canagliflozin 300 mg: Baseline to Week 104</title>
          <description>Each patient received 300 mg of canagliflozin once daily for 104 weeks in addition to being on a stable antihyperglycemic (AHA) regimen at the time of study entry. Data are presented for Baseline to Week 104</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.0 / 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pouchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cartilage atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Angiosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hypoventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Embolism arterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.0 / 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="166" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="169" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="169" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="44" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="236"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="241"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="236"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="241"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="236"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Franchise Medical Leader, Cardiovascular &amp; Metabolism Franchise</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

